Hydroxyapatite concerns, answered with the published research
If you've worked with hydroxyapatite-based bone substitutes before and walked away frustrated, you're not alone — and you're not wrong about what you saw. Brittleness, poor resorption, particle migration, and limited handling characteristics are well-documented limitations of conventional ceramic HAP. FlexiOss® was engineered specifically around these failure points by embedding HAP granules in a curdlan (β-1,3-glucan) polymer matrix rather than delivering ceramic alone. Below is what the peer-reviewed evidence actually shows for each concern — including where that evidence is still early-stage.
Unmodified ceramic hydroxyapatite is mechanically fragile: it has low fracture resistance, tends to crumble during handling, and can't be reshaped to fit an irregular bone cavity. FlexiOss addresses this structurally rather than chemically — the HAP granules are physically entrapped inside a curdlan triple-helix gel, which is what gives the composite its elasticity. In practice, that means soaking the material in sterile saline for 15 minutes and then hand-molding it directly into the curetted bone bed. Published cases, including a rabbit tibial-defect model and a human case series, report good conformity to irregular defect shapes during surgical handling.
Browse the published research
All claims on this page are drawn directly from the sources below. We'd rather you read the primary literature than take our word for it.
- Full FlexiOss publication bibliography
- Kotrych et al., J Clin Med 2025 — enchondroma case series
- Borkowski et al., J Biomed Mater Res B 2018 — behavior in human serum
- Borkowski et al., Mater Sci Eng C 2016 — bioactivity comparison
- Belcarz, Zima & Ginalska, Int J Pharm 2013 — antibiotic-loaded composite
- Misztal-Kunecka et al., Veterinary Sciences 2024 — veterinary applications
- FlexiOssOT randomized controlled trial (ongoing)
Evidence summarized here includes small case series and studies involving researchers affiliated with FlexiOss's own R&D program. Refer to the Instructions for Use and full regulatory documentation for complete safety information. This page is intended for healthcare professionals and does not constitute a clinical recommendation for any individual patient.